Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Histopathology. 2020 Jan;76(2):233-243. doi: 10.1111/his.13963. Epub 2019 Nov 13.
Immune checkpoint inhibitors (ICIs) improve survival across a range of malignancies but are also associated with a spectrum of gastrointestinal (GI) immune-related adverse events (GI-irAEs). The aims of this study were to explore the diagnostic value of gastric and duodenal biopsies and to address considerations in the differential diagnosis.
We identified 39 patients who were treated with ICIs and had a subsequent upper GI biopsy. We recorded clinical data and endoscopic findings, and reviewed their gastric, duodenal and colonic biopsies. Twenty-one (54%) patients were treated with an anti-programmed cell death protein 1 (PD-1)/anti-programmed cell death ligand 1 antibody alone, and 17 (44%) patients were treated with a combination of anti-cytotoxic T-lymphocyte-associated protein-4 and anti-PD-1 antibodies. Thirty-two (82%) patients presented with diarrhoea. Gastric alterations included periglandular inflammation and granulomas, and duodenal changes included villous blunting, intraepithelial lymphocytosis, granulomas, and neutrophilic activity. We recognised four patterns of colonic injury: (i) acute self-limiting colitis; (ii) lymphocytic colitis; (iii) collagenous colitis; and (iv) apoptosis-only. Twenty-nine (74%) and 10 (26%) patients were diagnosed clinically as positive and negative for GI-irAEs, respectively. Gastric periglandular inflammation (P = 0.004) and an increased number of colonic lamina propria mononuclear cells (P = 0.04) correlated with the clinical diagnosis of a GI-irAE. Histological alterations associated with ICI injury were more often identified in upper GI biopsies (71%) than in colonic biopsies (65%).
The morphological spectrum of ICI-related GI disease is broad, and mimics a range of infectious and inflammatory diseases. Gastric periglandular inflammation represents one of the more characteristic histological features of GI-irAEs. The study underscores the importance of a comprehensive review of upper and lower GI biopsies for the diagnosis of GI-irAEs.
免疫检查点抑制剂 (ICI) 改善了多种恶性肿瘤的生存率,但也与一系列胃肠道 (GI) 免疫相关不良事件 (GI-irAE) 相关。本研究旨在探讨胃和十二指肠活检的诊断价值,并解决鉴别诊断中的注意事项。
我们确定了 39 名接受 ICI 治疗且随后进行上 GI 活检的患者。我们记录了临床数据和内镜发现,并回顾了他们的胃、十二指肠和结肠活检。21 名(54%)患者单独接受抗程序性细胞死亡蛋白 1 (PD-1)/抗程序性细胞死亡配体 1 抗体治疗,17 名(44%)患者接受抗细胞毒性 T 淋巴细胞相关蛋白 4 和抗 PD-1 抗体联合治疗。32 名(82%)患者出现腹泻。胃改变包括腺周炎症和肉芽肿,十二指肠改变包括绒毛变钝、上皮内淋巴细胞增多、肉芽肿和中性粒细胞活性。我们识别出四种结肠损伤模式:(i)急性自限性结肠炎;(ii)淋巴细胞性结肠炎;(iii)胶原性结肠炎;和(iv)仅凋亡。29 名(74%)和 10 名(26%)患者的临床诊断分别为 GI-irAE 阳性和阴性。胃腺周炎症(P=0.004)和结肠固有层单核细胞数量增加(P=0.04)与 GI-irAE 的临床诊断相关。与 ICI 损伤相关的组织学改变在上 GI 活检中比在结肠活检中更常见(71% vs 65%)。
ICI 相关 GI 疾病的形态谱广泛,模仿一系列感染性和炎症性疾病。胃腺周炎症是 GI-irAE 的更具特征性组织学特征之一。该研究强调了全面审查上消化道和下消化道活检对 GI-irAE 诊断的重要性。